It were examined 70 young women with PCOS. It was established, that these patients have lower levels of folic acid than healthy women, 47 % — reduction below reference values of norms, 52.8 % — hyperhomocysteinemia. Folic acid treatment at a dose of 5 mg/day helped to normalize its levels for 12 week therapy at that at women with normal body weight normalization was faster. The concentration of homocysteine during treatment as high as indicators of healthy women at patients with normal weight for 12 weeks of therapy, and at patients with obesity — for 24 weeks. Determination in blood levels of folate and homocysteine should be included a comprehensive examination of this category of patients, particularly at the stage pregravid period.

The aim of the work was to study the relationship between levels of vitamin D, obesity and lipid profilein patients with polycystic ovary syndrome (PCOS).Materials and methods. The study involved 120 women: 60 patients with PCOS and 60 healthy women.All examined were divided into groups depending on body mass index (BMI): patients with PCOS — 30 withBMI ≤ 25 kg/m2and 30 with BMI ≥ 25 kg/m2; healthy women — 30 with BMI ≤ 25 kg/m2and 30 withBMI ≥ 25 kg/m2. Results. Patients with a BMI of ≥ 25 kg/m2had a lower average level of vitamin D (P < 0,001) than patientswith a BMI of ≤ 25 kg/m2; among of them there was a higher percentage of women with a pronounceddeficiency (23.3% versus 13.3%) and deficiency (60% versus 50%) of vitamin D; nobody had not adequate levelsof vitamin D. It was established a negative correlation between the level of vitamin D and BMI (r = – 0.275;P < 0.05), waist circumference (r = – 0.604; P < 0.001), the coefficient of waist circumference/ hips circumference(r = – 0.512; P < 0.001). Abdominal type of adipose tissue distribution, which was observed among patients withboth overweight and normal weight, may be one of the factors contributing to dysregulation of metabolism of vitaminD in conditions of PCOS.Women with PCOS had lipid metabolism disorders with increased atherogenic and decreased levels of antiatherogeniclipid fractions wich was intensif with increasing body weight. It was established a negative correlationbetween the level of vitamin D and triglycerides (r = – 0.437; P < 0.001), and positive association with highdensity lipoprotein cholesterol (r = 0.492; P < 0.001).In healthy women, only a negative correlation between the concentration of vitamin D and BMI (r = – 0.562;P < 0.001) was establish and there was no association with other anthropometric indicators and indicators of theblood lipid spectrum.Conclusion. Patients with PCOS have a higher prevalence and severity of deficiency of vitamin D.Disruption of regulation of vitamin D metabolism may be a consequence of existing obesity, and a decrease invitamin D levels is an additional factor that increase the dyslipidemia that exists in PCOS.

It was examined 55 patients with PCOS that were divided into groups depending on the functional state of the thyroid gland: 21 women with autoimmune thyroiditis in euthyroid stage, 14 women with autoimmune thyroiditis which was combined with subclinical hypothyroidism, 20 — without a thyroid dysfunction. It was found that the euthyroid dysfunction aggravates the typical for the classic phenotype of PCOS the hormonal disorders — increase the total testosterone, the free androgen index and decrease the sex-steroid-binding globu­lin. The absence of a correlation between TTG and LH, LG / FSH indicates different mechanisms formation of PCOS and thyroid pathology.

Наведені дані щодо впливу монотерапії метформіном та комбінованої терапії метформіном з додаванням фолатів на рівень гомоцистеїну та фолієвої кислоти у хворих зі синдромом полікістозних яєчників. Монотерапія призводила до зниження інсулінорезистентності, індексу НОМА, помірного антиандрогенного ефекту, позитивно впливала на рівні ліпідів, при цьому показники фолієвої кислоти залишались низькими та відмічалось зростання концентрації гомоцистеїну в сироватці крові на 18,3 %. Комбінована терапія не посилювала терапевтичного впливу на вуглеводний обмін та гормональні показники, але призводила до підвищення вмісту фолатів на 12,4 % та зниження рівня гомоцистеїну на 14,3 % порівняно з вихідними значеннями.

It was a comparative analysis of clinical and hormonal parameters in women with normalmenstrual cycles and cystic degenerate ovaries, polycystic ovary syndrome (PCOS) patients andhealthy women. There were no significant differences in the content of testosterone, estradiol,dehydroepiandrosterone sulfate, 17-OH progesterone, prolactin and sex hormone binding globulinin the blood serum of healthy women and women with cystic degenerate ovaries. Indicators of antimullerian hormone in patients with cystic degenerate ovaries were significantly higher than in healthy,but lower than in patients with PCOS. As with PCOS levels of anti-mullerian hormone in women withovarian degenerate cystic positively correlated with ovarian volume, the number of antral follicles andthe level of luteinizing hormone. It is suggested that cystic degenerate ovaries are not normal, butrather — a milder phenotype of PCOS.